Cephalon, Inc. Settles Drug Marketing Investigation for $425 Million
Cephalon will pay $425 million under an agreement with the U.S. attorney in Philadelphia and the Justice Department over an investigation of the company’s sales and marketing practices.
The company also agreed to a misdemeanor violation of the Federal Food, Drug and Cosmetic Act and will enter into a corporate integrity agreement with the HHS Office of Inspector General.